US Patent

US8445524 — Solid forms of bendamustine hydrochloride

Method of Use · Assigned to Cephalon LLC · Expires 2029-03-26 · 3y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel solid forms of bendamustine hydrochloride and methods for preparing and using them.

USPTO Abstract

Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Drugs covered by this patent

bendamustine-hydrochloride (BENDAMUSTINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1402`	—	bendamustine-hydrochloride
`U-1402`	—	bendamustine-hydrochloride

Patent Metadata

Patent number: US8445524
Jurisdiction: US
Classification: Method of Use
Expires: 2029-03-26
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Cephalon LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.